Skip to content

A Novel Psychological Intervention for Adults With Bipolar Disorder and Attention Deficit Hyperactivity Disorder Comorbidity (VECTOR)

Bridging the Gap in the Study of Bipolar Disorder and Attention Deficit Hyperactivity Disorder: Impact of cognitiVE Reserve and funCtioning in a Newly Designed Treatment intervenTion for comORbidity (VECTOR)

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07039903
Acronym
VECTOR
Enrollment
68
Registered
2025-06-26
Start date
2025-09-01
Completion date
2027-12-31
Last updated
2025-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADHD, BD

Keywords

clinical trial, Cognitive Behavioral Therapy, Psychological treatment, Bipolar Disorder, Bipolar and Related Disorders, BD, Attention-Deficit Hyperactivity Disorder, ADHD, Functional remediation

Brief summary

Cognitive dysfunctions are present in Bipolar Disorder (BD) and Attention Deficit Hyperactivity Disorder (ADHD) and may negatively impact psychosocial functioning. Further, comorbid BD and ADHD (BD-ADHD) is prevalent, associated with an earlier BD onset and a less favorable prognosis. Nevertheless, there is a paucity of research dedicated to the characterization and treatment of comorbid BD-ADHD. This study aims to develop and evaluate the effectiveness of a novel psychological group intervention (VECTOR) for adults with BD-ADHD. VECTOR integrates elements from Cognitive Behavioral Therapy (CBT) for ADHD and Functional Remediation (FR) for BD. Eighty patients will be randomized (1:1) to receive either the VECTOR program (12 weekly group sessions) or treatment as usual (TAU). It is expected that the VECTOR program will result in greater improvements in functioning and symptom reduction compared to TAU.

Interventions

BEHAVIORALCognitive behavioral therapy (CBT) + Functional Remediation (FR)

VECTOR will provide a newly designed intervention, based on the adaptation of two existing evidence-based and effective interventions (CBT for ADHD and FR for BD)(Corrales et al., 2024; Torrent et al., 2013).

Sponsors

Hospital Clinic of Barcelona
CollaboratorOTHER
Hospital Universitari Vall d'Hebron Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Fulfill DSM-5 criteria for BDI or BDII and ADHD using the Structured Clinical Interview for DSM-5 and the Conners' Adult ADHD Diagnostic Interview (CAARS) * Aged ≥18 * Stable pharmacological treatment for at least the past three months. * Being in full or partial remission Young Mania Rating Scale (YMRS) ≤ 10, Hamilton Depression Rating Scale (HDRS) ≤ 14) at the time of the inclusion and assessment * ADHD rating scale≥24

Exclusion criteria

* Any comorbid psychiatric condition * Diagnosis of substance abuse disorder in the past 12 months * Intellectual disability (intelligence quotient \< 70) * Having any Central Nervous System illness, independent of primary psychiatric diagnosis, hampering neuropsychological performance * Participation in a structured psychological intervention during the study period.

Design outcomes

Primary

MeasureTime frameDescription
Clinical Global Impression - Severity (CGI-S)Baseline, post-treatment (12 weeks) and 12 monthsSeverity scale measuring global symptom severity. Assessed by a blind expert rater.
Functioning Assessment Short Test (FAST)Baseline, post-treatment (12 weeks) and 12 months24-item scale assessing disability in six functional domains: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships, and leisure time. Assessed by a blind expert rater.

Secondary

MeasureTime frameDescription
Change in the severity of ADHD symptomsBaseline, post-treatment (12 weeks) and 12 monthsAssessed by Connors' Adult ADHD Rating Scales Self-report form (CAARS-S:L), a self-report questionnaire evaluating the severity of ADHD symptoms across multiple domains, including inattention and hyperactivity/impulsivity.
Change in the Hamilton DepressionBaseline, post-treatment (12 weeks) and 12 monthsEach item is rated on either a 3-point or 5-point Likert-type scale, depending on the symptom being assessed, with higher scores indicating greater severity of depression. The total score for the HDRS-17 ranges from 0 to 52. Common domains evaluated include mood, guilt, suicide ideation, insomnia, anxiety, psychomotor changes, and somatic symptoms.
Change in the Young Mania Rating Scale (YMRS)Baseline, post-treatment (12 weeks) and 12 months11-item clinician-rated scale used to assess manic symptoms such as elevated mood, increased motor activity, sleep disturbance, irritability, and thought disorder. Higher scores reflect more severe manic symptoms. Assessed by a blind expert rater.
Change in attention - Trail Making Test Part A (TMT-A)Baseline, post-treatment (12 weeks) and 12 monthsTMT-A assesses processing speed and visual attention. Participants are asked to connect numbered circles in sequence as quickly as possible. Completion time is the outcome measure; shorter times indicate better performance.
Change in sustained attention - Conners' Continuous Performance Test (CPT)Baseline, post-treatment (12 weeks) and 12 monthsThe CPT is a computerized test that measures sustained attention and impulsivity by recording responses to a series of visual stimuli. Key outcomes include omission errors, commission errors, and reaction time variability.
Change in executive function - Wisconsin Card Sorting Test (WCST)Baseline, post-treatment (12 weeks) and 12 monthsThe WCST measures cognitive flexibility and executive functioning. Participants must match cards according to varying rules. Key outcomes include number of categories completed and perseverative errors.
Change in inhibitory control - Stroop TestBaseline, post-treatment (12 weeks) and 12 monthsThe Stroop Color-Word Test evaluates selective attention and inhibitory control by measuring the ability to name the color of the ink rather than reading the printed word. Interference score is commonly used.
Change in verbal fluency - Phonemic and Semantic Fluency (PMR)Baseline, post-treatment (12 weeks) and 12 monthsThe Verbal Fluency Test assesses executive control and language by requiring the participant to generate as many words as possible starting with a letter (phonemic) or within a category (semantic) in a limited time.
Change in cognitive flexibility - Trail Making Test Part B (TMT-B)Baseline, post-treatment (12 weeks) and 12 monthsTMT-B assesses cognitive flexibility, task-switching, and executive control. Participants alternate between numbers and letters in sequence (e.g., 1-A-2-B...). Completion time is recorded, with shorter times indicating better performance.
Change in the ADHD-Rating Scale (ADHD-RS)Baseline, post-treatment (12 weeks) and 12 monthsThe ADHD-RS is an 18-items scale self-report version for assessing symptoms for ADHD DSM-IV. It consists of a subscale of inattention (IN, 9-items), another of hyperactivity/impulsivity (H / I, 9-items) and the total (TOT, 18-items). The interviewees are asked about the frequency of the symptoms over the past 6 months.

Other

MeasureTime frameDescription
CSQ-812 weeks (post)Client Satisfaction Questionnaire-8 (self-report) - in order to evaluate the treatment satisfaction
Working Alliance Inventory12 weeks (post)The Working Alliance Inventory (WAI) is a self-report questionnaire designed to assess the quality of the therapeutic relationship. It evaluates three key components: agreement on therapeutic goals, agreement on tasks, and the emotional bond between therapist and patient. Higher scores indicate a stronger working alliance.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026